CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Riluzoledrug
Likely dose
Riluzole 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00895752
NCT00895752Phase 4Completed
CompareCT.gov

Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay

Indiana University·interventional·Posted May 8, 2009·Updated Apr 18, 2017

In Brief

A Phase 4 clinical trial evaluating Riluzole for Fragile X Syndrome. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effectiveness and tolerability of riluzole in adults with Fragile X Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesUnited States
CollaboratorsIndiana Clinical and Translational Sciences Institute

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.2 years ago

Interventions

Riluzoledrug

Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.